WESTMONT, Ill.--(BUSINESS WIRE)--July 6, 2006--Targeted Molecular Diagnostics, LLC (TMD) announces the publication of clinical data from their Targeted Diagnostics Advocacy Program (tdap(TM)) at the 42nd annual meeting of the American Society for Clinical Oncology (ASCO) in Atlanta, GA. During the poster presentation session on June 5th, TMD presented data from their ongoing tdap(TM) study - Heterogeneity of Epidermal Growth Factor Receptor (EGFR) Expression and Variation in Immunohistochemistry (IHC) Testing May Affect Access to EGFR-Targeted Therapy in Patients with Advanced Colorectal Cancer (CRC). The study showed that patient access to potentially beneficial therapy is severely compromised by variation in testing procedures between laboratories and that the tdap(TM) has improved access through the assessment of multiple tumor specimens and standardization in a central laboratory. Of 245 U.S. study patients previously reported clinically to be EGFR-negative and inappropriate for treatment, 68% (167/245) were found to be EGFR-positive when re-tested through the tdap(TM).
